Novo Nordisk has terminated its partnership with Hims & Hers due to concerns over the telehealth company’s continued sales and promotion of compounded, unapproved versions of the weight-loss drug Wegovy. Novo Nordisk stated that Hims & Hers did not comply with legal restrictions that prohibit mass sales of compounded drugs after the end of the official Wegovy shortage, criticizing the company for deceptive marketing and prioritizing patient safety as the main reason for ending the collaboration.
Full Story: CNBC (6/23)